SPRR2A and neoplasm: We have shown that Ad-RTS-mIL-12+veledimex elicited a dose-related increase in tumor IL-12 which in turn elicited a dose-related increase in CD3+CD8+cytotoxic T cells concomitant with a reduction in FOXP3+ regulatory T cells.